How BTK Degraders Work in CLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at CLL patients who are taking or may take a BTK degrader (a newer type of targeted therapy) to find out what factors influence how well the treatment works. It aims to help doctors understand who benefits most from this approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic lymphocytic leukemia (CLL).
- You are either currently taking a BTK degrader (a targeted therapy for CLL) or your doctor has recommended one.
- You are willing to give your permission (informed consent) to take part in the study.
- You are covered by social security health insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what happens to patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after they stop taking a type of targeted therapy called a BTK inhibitor. It aims to understand treatment patterns and outcomes to help guide future care.
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
This trial tests whether adding venetoclax to your current BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) works better than taking the BTK inhibitor alone. It's for veterans with CLL or SLL who have been on a BTK inhibitor for at least six months and have not had their disease get worse on that therapy.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial tests whether NX-5948 is more effective than pirtobrutinib for people with CLL or SLL whose disease has gotten worse after an earlier BTK inhibitor treatment. It aims to find a better option for those who have already tried one type of therapy.
This study looks at how well a type of targeted therapy called a BTK inhibitor works for people with chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow. It includes both people who have never been treated and those whose cancer came back or didn't get better. The goal is to understand real-world outcomes and help guide future care.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.